In a post hoc ATTRibute-CM analysis, patient-reported heart failure health status recovered after a first cardiovascular-related hospitalization among acoramidis recipients, while continuing to decline...
In a post hoc analysis of 611 ATTRibute-CM participants, acoramidis was associated with a 41% lower risk of first outpatient worsening heart failure than placebo over 30 months.
Recent US claims data offer insight into how transthyretin amyloid cardiomyopathy’s diagnosed incidence, prevalence, and associated clinical burden have changed over time.
In this video, Rachel Lampert, MD, Robert W. Berliner Professor of Internal Medicine at the Yale School of Medicine, reviews her presentation at the American College of Cardiology 2025 Annual Meeting,...